InflaRx (IFRX) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $5.00 price target on the stock.
InflaRx (IFRX) had its "buy" rating reaffirmed by Guggenheim. They now have a $14.00 price target on the stock.
InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor
InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium
InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting